{
  "id": 3607,
  "text": "1597.Irvin, W.P., et al.A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.Cancer 82, 328-333 (1998).1598.Look, K.Y., et al.A phase II trial of CPT11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1597.Irvin, W.P., et al.A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.Cancer 82, 328-333 (1998).1598.Look, K.Y., et al.A phase II trial of CPT11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据现有的临床研究，伊立替康（CPT-11）在治疗宫颈鳞状细胞癌患者中表现出了一定的有效性。具体来说，伊立替康已在晚期和复发性宫颈鳞状细胞癌的治疗中被研究作为二线或三线化疗药物。一个关键的二期临床试验显示，伊立替康在这类患者中能够提供部分反应，并在某些病例中显著延长疾病稳定时间。然而，其效果通常取决于个体患者的病情以及之前接受的治疗方案。此外，治疗过程中可能出现与伊立替康相关的常见不良反应，如胃肠道症状和白细胞减少等，因此在使用时需要密切监测和管理。",
  "query": "根据现有的临床研究，CPT-11（伊立替康）在治疗宫颈鳞状细胞癌患者中的效用如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据现有的临床研究，CPT-11（伊立替康）在治疗宫颈鳞状细胞癌患者中的效用如何？\n\n<reference text>: 1597.Irvin, W.P., et al.A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.Cancer 82, 328-333 (1998).1598.Look, K.Y., et al.A phase II trial of CPT11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据现有的临床研究，伊立替康（CPT-11）在治疗宫颈鳞状细胞癌患者中表现出了一定的有效性。具体来说，伊立替康已在晚期和复发性宫颈鳞状细胞癌的治疗中被研究作为二线或三线化疗药物。一个关键的二期临床试验显示，伊立替康在这类患者中能够提供部分反应，并在某些病例中显著延长疾病稳定时间。然而，其效果通常取决于个体患者的病情以及之前接受的治疗方案。此外，治疗过程中可能出现与伊立替康相关的常见不良反应，如胃肠道症状和白细胞减少等，因此在使用时需要密切监测和管理。"
}